pentetic acid has been researched along with Ovarian Neoplasms in 46 studies
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epithelial ovarian cancer (EOC) is usually diagnosed at an advanced stage and has poor prognosis." | 1.72 | Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer. ( Chang, MC; Chen, CA; Chen, IC; Chiang, PF; Chiang, YC; Huang, CY; Kuo, YJ; Peng, CL, 2022) |
| "Ovarian cancer is the most lethal gynecologic malignancy, often diagnosed at advanced stage leading to poor prognosis." | 1.35 | Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media. ( Kalchenko, V; Kohen, F; Meir, G; Migalovich, HS; Neeman, M; Nevo, N, 2009) |
| "DFO and DTPA were cytotoxic to ovarian cancer cells in a dose- and time-dependent manner." | 1.33 | Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. ( Brard, L; Granai, CO; Swamy, N, 2006) |
| "Colon cancer is the second most common cause of cancer mortality." | 1.30 | Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. ( Bohdiewicz, PJ, 1998) |
| " The purpose of this study was to determine a dosing schema of an adenoviral vector encoding the human somatostatin receptor subtype 2 (AdCMVhSSTr2) for achieving the highest tumor localization of [(111)In]-DTPA-D-Phe1-octreotide, which binds to this receptor, in a human ovarian cancer model as a prelude to future therapy studies." | 1.30 | In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. ( Bright, SJ; Buchsbaum, DJ; Curiel, DT; Della Manna, D; Kirkman, RL; Mayo, MS; McLean, SF; Myracle, AD; Olsen, CC; Rogers, BE, 1999) |
| " The pharmacokinetic study showed a retention half-life of 25." | 1.29 | Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. ( Bardiès, M; Chatal, JF; Faivre-Chauvet, A; Imai, S; Kraeber-Bodéré, F; Le Boterff, J; Mishra, A; Thédrez, P, 1996) |
| "VX2 carcinoma (squamous cell carcinoma) was implanted in either the brain, lung, ovary, bone or muscle of rabbits." | 1.29 | Contrast-enhanced MRI with gadodiamide injection in rabbit carcinoma models. ( Furuhama, K; Hirose, T; Ikehira, H; Jinbo, T; Kato, H; Miyahara, K; Sato, M; Sugihara, H; Tateno, Y; Yamada, K, 1996) |
| " Changes in relaxation times in normal and abnormal tissues following contrast medium, toxicity and dosage of gadolinium-DTPA, and MRI pulse sequence techniques are reviewed." | 1.27 | Contrast-enhanced magnetic resonance imaging of tumours of the central nervous system: a clinical review. ( Graif, M; Steiner, RE, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.52) | 18.7374 |
| 1990's | 30 (65.22) | 18.2507 |
| 2000's | 7 (15.22) | 29.6817 |
| 2010's | 5 (10.87) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MC | 1 |
| Chiang, PF | 1 |
| Kuo, YJ | 1 |
| Peng, CL | 1 |
| Chen, IC | 1 |
| Huang, CY | 1 |
| Chen, CA | 1 |
| Chiang, YC | 1 |
| Feldmann, DP | 1 |
| Jones, S | 1 |
| Douglas, K | 1 |
| Shields, AF | 1 |
| Merkel, OM | 1 |
| Liu, P | 3 |
| Boyle, AJ | 3 |
| Lu, Y | 3 |
| Adams, J | 1 |
| Chi, Y | 1 |
| Reilly, RM | 3 |
| Winnik, MA | 3 |
| Migalovich, HS | 1 |
| Kalchenko, V | 1 |
| Nevo, N | 1 |
| Meir, G | 1 |
| Kohen, F | 1 |
| Neeman, M | 1 |
| Nayak, TK | 1 |
| Garmestani, K | 1 |
| Baidoo, KE | 1 |
| Milenic, DE | 1 |
| Brechbiel, MW | 2 |
| Weinrich, D | 1 |
| Scollard, DA | 1 |
| Ngo Njock Mbong, G | 1 |
| Siegel, BA | 1 |
| Dehdashti, F | 1 |
| Mutch, DG | 1 |
| Podoloff, DA | 2 |
| Wendt, R | 1 |
| Sutton, GP | 1 |
| Burt, RW | 1 |
| Ellis, PR | 1 |
| Mathias, CJ | 1 |
| Green, MA | 1 |
| Gershenson, DM | 1 |
| Adams, GP | 1 |
| Shaller, CC | 1 |
| Dadachova, E | 1 |
| Simmons, HH | 1 |
| Horak, EM | 1 |
| Tesfaye, A | 1 |
| Klein-Szanto, AJ | 1 |
| Marks, JD | 1 |
| Weiner, LM | 1 |
| Brard, L | 1 |
| Granai, CO | 1 |
| Swamy, N | 1 |
| Orlova, A | 2 |
| Rosik, D | 1 |
| Sandström, M | 1 |
| Lundqvist, H | 1 |
| Einarsson, L | 1 |
| Tolmachev, V | 2 |
| Tran, T | 1 |
| Widström, C | 1 |
| Engfeldt, T | 1 |
| Eriksson Karlström, A | 1 |
| Müller, C | 1 |
| Schibli, R | 1 |
| Krenning, EP | 1 |
| de Jong, M | 1 |
| Low, RN | 1 |
| Carter, WD | 1 |
| Saleh, F | 1 |
| Sigeti, JS | 1 |
| Kosmas, C | 1 |
| Maraveyas, A | 1 |
| Gooden, CS | 1 |
| Snook, D | 1 |
| Epenetos, AA | 1 |
| Bohdiewicz, PJ | 2 |
| Scott, GC | 1 |
| Juni, JE | 1 |
| Fink-Bennett, D | 1 |
| Wilner, F | 1 |
| Nagle, C | 1 |
| Dworkin, HJ | 1 |
| Yamashita, Y | 2 |
| Torashima, M | 2 |
| Hatanaka, Y | 2 |
| Harada, M | 1 |
| Higashida, Y | 1 |
| Takahashi, M | 2 |
| Mizutani, H | 1 |
| Tashiro, H | 1 |
| Iwamasa, J | 1 |
| Miyazaki, K | 2 |
| Hempling, RE | 1 |
| Piver, MS | 1 |
| Baker, TR | 1 |
| Bakshi, S | 1 |
| Gilani, SS | 1 |
| Cannistra, SA | 1 |
| Neal, CE | 2 |
| Baker, MR | 1 |
| Hilgers, RD | 1 |
| Fanning, J | 1 |
| Burke, RC | 1 |
| Snodgrass, J | 1 |
| Cull, RD | 1 |
| Kim, EE | 2 |
| Kasi, LP | 1 |
| Surwit, EA | 2 |
| Childers, JM | 1 |
| Krag, DN | 1 |
| Katterhagen, JG | 1 |
| Gallion, HH | 1 |
| Waggoner, S | 1 |
| Mann, WJ | 1 |
| Tibben, JG | 1 |
| Thomas, CM | 1 |
| Massuger, LF | 1 |
| Segers, MF | 1 |
| Schijf, CP | 1 |
| Corstens, FH | 1 |
| Boerman, OC | 1 |
| Reuter, M | 1 |
| Steffens, JC | 1 |
| Schüppler, U | 1 |
| Muhle, C | 1 |
| Brinkmann, G | 1 |
| Kohl, A | 1 |
| Weisner, D | 1 |
| Lüttges, J | 1 |
| Spielmann, RP | 1 |
| Heller, M | 1 |
| Method, MW | 1 |
| Serafini, AN | 1 |
| Averette, HE | 1 |
| Rodriguez, M | 1 |
| Penalver, MA | 1 |
| Sevin, BU | 1 |
| Kraeber-Bodéré, F | 1 |
| Mishra, A | 1 |
| Thédrez, P | 2 |
| Faivre-Chauvet, A | 1 |
| Bardiès, M | 1 |
| Imai, S | 1 |
| Le Boterff, J | 1 |
| Chatal, JF | 2 |
| Yamada, K | 1 |
| Jinbo, T | 1 |
| Miyahara, K | 1 |
| Sato, M | 1 |
| Hirose, T | 1 |
| Kato, H | 1 |
| Tateno, Y | 1 |
| Ikehira, H | 1 |
| Sugihara, H | 1 |
| Furuhama, K | 1 |
| Johnson, DL | 1 |
| Cornwell, VL | 1 |
| Markwell, S | 1 |
| Nguyen, BD | 1 |
| Regan, F | 1 |
| Okamura, H | 1 |
| Mardirossian, G | 1 |
| Brill, AB | 1 |
| Harwood, SJ | 1 |
| Olsen, J | 1 |
| Dwyer, KA | 1 |
| Siegel, JA | 1 |
| Rogers, BE | 1 |
| McLean, SF | 1 |
| Kirkman, RL | 1 |
| Della Manna, D | 1 |
| Bright, SJ | 1 |
| Olsen, CC | 1 |
| Myracle, AD | 1 |
| Mayo, MS | 1 |
| Curiel, DT | 1 |
| Buchsbaum, DJ | 1 |
| Inoue, T | 1 |
| Li, C | 1 |
| Yang, DJ | 1 |
| Higuchi, T | 1 |
| Oriuchi, N | 1 |
| Yu, D | 1 |
| Milas, L | 1 |
| Hunter, N | 1 |
| Wallace, S | 1 |
| Pinkas, L | 1 |
| Robins, PD | 1 |
| Forstrom, LA | 1 |
| Mahoney, DW | 1 |
| Mullan, BP | 1 |
| Reilly, R | 1 |
| Lee, N | 1 |
| Houle, S | 1 |
| Law, J | 1 |
| Marks, A | 1 |
| Gallup, DG | 1 |
| Maguire, RT | 1 |
| Jusko, WJ | 1 |
| Kung, LP | 1 |
| Schmelter, RF | 1 |
| Stevens, SK | 1 |
| Hricak, H | 1 |
| Stern, JL | 1 |
| Hötzinger, H | 1 |
| Salbeck, R | 1 |
| Toedt, C | 1 |
| Beyer, HK | 1 |
| Hnatowich, DJ | 1 |
| Chinol, M | 1 |
| Siebecker, DA | 1 |
| Gionet, M | 1 |
| Griffin, T | 1 |
| Doherty, PW | 1 |
| Hunter, R | 1 |
| Kase, KR | 1 |
| Fumoleau, P | 1 |
| Saccavini, JC | 1 |
| Curtet, C | 1 |
| Bianco-Arco, A | 1 |
| Chetanneau, A | 1 |
| Peltier, P | 1 |
| Kremer, M | 1 |
| Guillard, Y | 1 |
| Graif, M | 1 |
| Steiner, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas[NCT01469975] | Phase 1 | 20 participants (Actual) | Interventional | 2011-12-31 | Terminated (stopped due to Too slow accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pentetic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
Topics: Adult; Aged; Antibodies, Monoclonal; Colorectal Neoplasms; Diagnostic Errors; Female; Humans; Indium | 1999 |
5 trials available for pentetic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.
Topics: Antibodies; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin G; | 1995 |
Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antigens, Neoplasm; Female; Glycoproteins; Humans; Indium Ra | 1993 |
The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 1996 |
Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
Topics: Adult; Antibodies, Monoclonal; Female; Humans; Indium Radioisotopes; Neoplasm Recurrence, Local; Neo | 1992 |
Impact of 111In-CYT-103 on the surgical management of patients with ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Indium Radioisotopes; Middle | 1992 |
40 other studies available for pentetic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer.
Topics: Animals; Antibodies, Neutralizing; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chitina | 2022 |
Microfluidic Assembly of siRNA-Loaded Micelleplexes for Tumor Targeting in an Orthotopic Model of Ovarian Cancer.
Topics: Animals; Cell Line, Tumor; Female; Heterografts; Humans; Mice; Microfluidics; Nanoparticles; Ovarian | 2019 |
Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
Topics: Acrylic Resins; Animals; Antibodies, Monoclonal; Biotin; Cell Line, Tumor; Chelating Agents; Ethylen | 2015 |
Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media.
Topics: Animals; Antineoplastic Agents; Biological Transport; Endocytosis; Female; Humans; Isoflavones; Mice | 2009 |
PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevaciz | 2011 |
Biotinylated polyacrylamide-based metal-chelating polymers and their influence on antigen recognition following conjugation to a trastuzumab Fab fragment.
Topics: Acrylic Resins; Antibodies, Monoclonal, Humanized; Biotin; Biotinylation; Breast Neoplasms; Cell Lin | 2012 |
The effect of metal-chelating polymers (MCPs) for 111In complexed via the streptavidin-biotin system to trastuzumab Fab fragments on tumor and normal tissue distribution in mice.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biotin; Cell Line, Tumor; Chelati | 2013 |
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.
Topics: Adult; Aged; Carrier Proteins; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Indium Ra | 2003 |
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Immunoglobulin Variable Region; Immunot | 2004 |
Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Topics: Animals; Apoptosis; Caspases; Cell Growth Processes; Cell Line, Tumor; Deferoxamine; Enzyme Activati | 2006 |
Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
Topics: Animals; Antibodies, Monoclonal; Cell Survival; Female; Ligands; Metabolic Clearance Rate; Mice; Org | 2007 |
Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Genes, erbB-2; Hu | 2007 |
Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer.
Topics: Animals; Autoradiography; Carrier Proteins; Cell Line, Tumor; Female; Folate Receptors, GPI-Anchored | 2008 |
Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT.
Topics: Abdominal Neoplasms; Antibodies, Monoclonal; Contrast Media; Drug Combinations; Female; Fluorocarbon | 1995 |
Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations.
Topics: Aged; Antibodies, Monoclonal; Colorectal Neoplasms; Deoxyglucose; Female; Fluorine Radioisotopes; Fl | 1995 |
Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging.
Topics: Adnexal Diseases; Adolescent; Adult; Aged; Contrast Media; Fallopian Tube Neoplasms; Female; Gadolin | 1995 |
Immunoscintigraphy using 111InCyt103 prior to second look laparotomy in ovarian cancer. A pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Carcinoma; Female; Hu | 1994 |
111In-CYT-103 immunoscintigraphy in ovarian cancer.
Topics: Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Female; Humans; Indium Radioisotop | 1993 |
In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
Topics: Antibodies, Monoclonal; Female; Humans; Indium Radioisotopes; Laparotomy; Middle Aged; Neoplasm Recu | 1993 |
Challenges in immunoscintigraphy of ovarian cancer.
Topics: Antibodies, Monoclonal; Female; Humans; Indium Radioisotopes; Oligopeptides; Ovarian Neoplasms; Pent | 1993 |
Oncoscint for detection of disseminated colorectal and ovarian cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Colorectal Neoplasms; Female; Humans; Indium Radioisotopes; | 1993 |
Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Neoplasm; Chelating Agents; | 1995 |
[Preoperative differential diagnosis of cystic adnexal tumors: double-contrast MRT].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Contrast Media; Cystadenocarcinoma; Cystadenoma; Dia | 1996 |
Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer.
Topics: Animals; Cystadenocarcinoma, Serous; Female; Humans; Isothiocyanates; Isotope Labeling; Mice; Mice, | 1996 |
Contrast-enhanced MRI with gadodiamide injection in rabbit carcinoma models.
Topics: Animals; Bone Neoplasms; Brain Neoplasms; Carcinoma, Squamous Cell; Contrast Media; Female; Gadolini | 1996 |
Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
Topics: Abdomen; Antibodies, Monoclonal; Carcinoma; Colorectal Neoplasms; Female; Femur; Humans; Ilium; Indi | 1996 |
In-111 CYT-103 immunoscintigraphy of isolated splenic metastasis from ovarian carcinoma.
Topics: Adult; Antibodies, Monoclonal; Cystadenocarcinoma, Serous; Female; Humans; Indium Radioisotopes; Oli | 1997 |
Characterization of sonographically indeterminate ovarian tumors with MR imaging. A logistic regression analysis.
Topics: Contrast Media; Diagnosis, Computer-Assisted; Female; Gadolinium; Gadolinium DTPA; Humans; Logistic | 1997 |
Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18.
Topics: Antibodies, Monoclonal; Colorectal Neoplasms; Female; Humans; Indium Radioisotopes; Male; Oligopepti | 1998 |
Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
Topics: Aged; Antibodies, Monoclonal; Clinical Trials as Topic; Colonic Neoplasms; Drug Approval; Female; Hu | 1998 |
In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Hormonal; Binding, Competitive; Female; Genetic Vector | 1999 |
Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel.
Topics: Animals; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Fibrosarcoma; Liver; Mammary N | 1999 |
In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111.
Topics: Antibodies, Monoclonal; Ascitic Fluid; Drug Stability; Edetic Acid; Female; Humans; In Vitro Techniq | 1992 |
OncoScint image atlas.
Topics: Antibodies, Monoclonal; Atlases as Topic; Colorectal Neoplasms; Female; Humans; Indium Radioisotopes | 1992 |
Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Half-Life; Humans; Indium Radioisoto | 1992 |
Ovarian lesions: detection and characterization with gadolinium-enhanced MR imaging at 1.5 T.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Contrast Media; Drug Combinations; Female; Gadolinium; G | 1991 |
[Initial experience with the use of oral gadolinium-DTPA in nuclear magnetic resonance tomography of the pelvis].
Topics: Administration, Oral; Adult; Aged; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic Resonan | 1990 |
Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody.
Topics: Animals; Antibodies, Monoclonal; Female; Humans; Immunization; Injections, Intraperitoneal; Mice; Mi | 1988 |
Immunoscintigraphy of recurrences of gynecologic carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antigens, Neoplasm; Antigens, Tumor-Associated, | 1987 |
Contrast-enhanced magnetic resonance imaging of tumours of the central nervous system: a clinical review.
Topics: Astrocytoma; Brain Neoplasms; Breast Neoplasms; Female; Gadolinium; Humans; Magnetic Resonance Spect | 1986 |